These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28334539)

  • 21. Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges.
    Blumer I; Clement M
    Clin Ther; 2017 Aug; 39(8S2):S1-S11. PubMed ID: 27871780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of non-insulin-dependent diabetes mellitus with metformin.
    Guthrie R
    J Am Board Fam Pract; 1997; 10(3):213-21. PubMed ID: 9159660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy.
    Pawaskar MD; Blickensderfer AL; Hoogwerf BJ; Quimbo R; Wade R
    J Med Econ; 2011; 14(6):705-8. PubMed ID: 21892855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.
    Duckworth W; Davis SN
    J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
    Berard L; MacNeill G
    Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
    Buse JB; Vilsbøll T; Thurman J; Blevins TC; Langbakke IH; Bøttcher SG; Rodbard HW;
    Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.
    Buturovic BA; Ristic LB; Narancic AM
    Med Arch; 2014 Oct; 68(5):313-6. PubMed ID: 25568561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diabetes mellitus type 1 and 2. Flexible therapy with insulin degludec].
    Rausch R
    Med Monatsschr Pharm; 2014 Jul; 37(7):273-4. PubMed ID: 25065174
    [No Abstract]   [Full Text] [Related]  

  • 29. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study).
    Weinrauch LA; D'Elia JA; Finn P; Lewis EF; Desai AS; Claggett BL; Cooper ME; McGill JB
    Diabetes Res Clin Pract; 2016 Mar; 113():143-51. PubMed ID: 26830074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
    Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
    Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus.
    Lloyd A; Nafees B; Barnett AH; Heller S; Ploug UJ; Lammert M; Bøgelund M
    Clin Ther; 2011 Sep; 33(9):1258-67. PubMed ID: 21862132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised?
    Bell DS
    Drugs; 2007; 67(13):1813-27. PubMed ID: 17722952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered?
    Spollett GR
    J Am Acad Nurse Pract; 2012 Apr; 24 Suppl 1():249-59. PubMed ID: 22564101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic treatment of type 2 diabetes: injectable medications.
    Tran L; Zielinski A; Roach AH; Jende JA; Householder AM; Cole EE; Atway SA; Amornyard M; Accursi ML; Shieh SW; Thompson EE
    Ann Pharmacother; 2015 Jun; 49(6):700-14. PubMed ID: 25802244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study.
    Dankers M; Hek K; Nelissen-Vrancken M; Houweling ST; Mantel-Teeuwisse A; van Dijk L
    Br J Gen Pract; 2022 Jun; 72(719):e430-e436. PubMed ID: 35606162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weight beneficial treatments for type 2 diabetes.
    Meneghini LF; Orozco-Beltran D; Khunti K; Caputo S; Damçi T; Liebl A; Ross SA
    J Clin Endocrinol Metab; 2011 Nov; 96(11):3337-53. PubMed ID: 21900381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2016 Feb; 18 Suppl 1():S43-55. PubMed ID: 26836429
    [No Abstract]   [Full Text] [Related]  

  • 40. The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.
    Saunders H; Pham B; Loong D; Mishra S; Ashoor HM; Antony J; Darvesh N; Bains SK; Jamieson M; Plett D; Trivedi S; Yu CH; Straus SE; Tricco AC; Isaranuwatchai W
    Value Health; 2022 Jul; 25(7):1235-1252. PubMed ID: 35341688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.